Message from the CEO S napshot Business Strategy Review of Operations Corporate Governance Financial Section 9 Annual Report 2014 _  Astellas Pharma Inc.  Note: In the information about pharmaceutical products in this report, market size, market share and product ranking are sourced from IMS Health  Information Services.  ©2013 IMS Health  Calculated based on IMS MIDAS 2014Q1 MAT Reprinted with permission http://www.astellas.com/  en/csr/ http://www.astellas.com/  en/ir/ http://www.astellas.com/ en/ wEBSiTES Information about pharmaceutical products (including products currently in development) has  been included. This content is not intended to constitute an advertisement or medical advice.  Statements made in this annual report with respect to current plans, estimates, strategies and  beliefs and other statements of Astellas that are not historical facts are forward-looking statements  about the future performance of Astellas. These statements are based on management’s current  assumptions and beliefs in light of the information currently available to it and involve known and  unknown risks and uncertainties. Consequently, undue reliance should not be placed on these  statements. Astellas cautions the reader that a number of important factors could cause actual  results to differ materially from those discussed in the forward-looking statements. Such factors  include, but are not limited to: (i) changes in general economic conditions and in the  Pharmaceutical Affairs Law and other laws and regulations relating to markets of Astellas, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of  Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to  effectively research and develop products accepted by customers in highly competitive markets,  and (vi) infringements of intellectual property rights of third parties. notes To make the report effective as a tool for communicating with our many  stakeholders, we have used charts, photographs and other devices to make it  easy to understand. Astellas has adopted the International Financial Reporting Standards (IFRS),  effective from fiscal 2013. Generally the information in this report is based on IFRS;  however, in order to facilitate comparison with information from previous years,  some sections are presented following J-GAAP, with an accompanying note.  The basis of this report is to provide an overview of the activities of Astellas  Pharma Inc. and its consolidated subsidiaries worldwide in fiscal 2013, which  covers the period from April 1, 2013 to March 31, 2014. In places where the  period or scope differs from these parameters, we have provided clarification.  This report also includes the latest information available at the time of publishing.  The figures indicated in the fiscal 2013 status report for the field of “Environment,”  however, present the results for fiscal 2013 (April 1, 2013 to March 31, 2014) in  Japan and the calendar year 2013 (January 1, 2013 to December 31, 2013) for  overseas operations. Furthermore, in the environment field, the report covers all  business sites in Japan and only manufacturing sites overseas. With the aim of deepening stakeholders’ understanding of our business activities  and CSR-based management, which is the basis for those activities, we have  integrated our Annual Report with our CSR Report, and now publish an integrated  Annual Report. Astellas is included in the following  global “social responsible investment  (SRI) indexes.” inclusion in SRi indexes Editorial policy CORPORATE WEBSITE INVESTOR RELATIONS CORPORATE SOCIAL  RESPONSIBILITy